ADYX OTC
Adynxx, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -66.7%
5Y: -99.9%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0001-0.0401
Volume16,300
Avg Volume15,032
Beta-8.54
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORichard Orr
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date1998-12-18
Websiteadynxx.com
100 Pine Street
San Francisco, CA 94111
US
San Francisco, CA 94111
US
415-512-7740
About Adynxx, Inc.
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| FLESHER GREGORY J. | 0 | — | 2019-07-22 | |
| GONZALEZ DINA | 26,358 | $3.06 | 2019-05-29 | |
| GONZALEZ DINA | 1,577 | $1.11 | 2019-05-29 | |
| GONZALEZ DINA | 1,577 | $1.39 | 2019-05-29 | |
| TPG Group Holdings ( | 0 | — | 2019-05-03 |